AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers - PubMed
6 hours ago
- #AXL-SHC1 signaling
- #HER2-targeted therapy resistance
- #lung and gastric cancer
- The AXL-SHC1 signaling axis is identified as a mechanism of adaptive resistance to HER2-targeted tyrosine kinase inhibitors (TKIs) in HER2-aberrant lung and gastric cancers.
- AXL receptor activation by HER2-TKIs sustains cell survival through interactions with EGFR, HER2, and HER3, mediated by the SHC1BP-SHC1 axis.
- Inhibition of AXL enhances HER2-TKI-induced apoptosis and significantly delays tumor regrowth in xenograft models of AXL-overexpressing cells.
- Patients with HER2-aberrant lung and gastric cancers showing high AXL expression may benefit from initial combination therapy with an AXL inhibitor.